GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Siegfried Holding AG (XSWX:SFZN) » Definitions » EV-to-EBIT

Siegfried Holding AG (XSWX:SFZN) EV-to-EBIT : 23.39 (As of May. 16, 2024)


View and export this data going back to 1973. Start your Free Trial

What is Siegfried Holding AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Siegfried Holding AG's Enterprise Value is CHF3,735 Mil. Siegfried Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF160 Mil. Therefore, Siegfried Holding AG's EV-to-EBIT for today is 23.39.

The historical rank and industry rank for Siegfried Holding AG's EV-to-EBIT or its related term are showing as below:

XSWX:SFZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.14   Med: 21.87   Max: 49.83
Current: 23.38

During the past 13 years, the highest EV-to-EBIT of Siegfried Holding AG was 49.83. The lowest was 8.14. And the median was 21.87.

XSWX:SFZN's EV-to-EBIT is ranked worse than
61.62% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.74 vs XSWX:SFZN: 23.38

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Siegfried Holding AG's Enterprise Value for the quarter that ended in Dec. 2023 was CHF3,591 Mil. Siegfried Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF160 Mil. Siegfried Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 4.45%.


Siegfried Holding AG EV-to-EBIT Historical Data

The historical data trend for Siegfried Holding AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Siegfried Holding AG EV-to-EBIT Chart

Siegfried Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.82 34.71 28.16 11.01 22.49

Siegfried Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.16 - 11.01 - 22.49

Competitive Comparison of Siegfried Holding AG's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Siegfried Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Siegfried Holding AG's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Siegfried Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Siegfried Holding AG's EV-to-EBIT falls into.



Siegfried Holding AG EV-to-EBIT Calculation

Siegfried Holding AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3735.157/159.676
=23.39

Siegfried Holding AG's current Enterprise Value is CHF3,735 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Siegfried Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF160 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Siegfried Holding AG  (XSWX:SFZN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Siegfried Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=159.676/3591.289825
=4.45 %

Siegfried Holding AG's Enterprise Value for the quarter that ended in Dec. 2023 was CHF3,591 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Siegfried Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was CHF160 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Siegfried Holding AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Siegfried Holding AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Siegfried Holding AG (XSWX:SFZN) Business Description

Traded in Other Exchanges
Address
Untere Bruehlstrasse 4, Zofingen, CHE, CH-4800
Siegfried Holding AG is a biotechnology company that focuses on primary and secondary drug manufacturing. The company develops and manufactures active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. Siegfried also offers the development and production of finished dosage forms, including sterile fillings. The company broadly offers complex oral and sterile formulations of drug products available for custom development and manufacturing, as well as licensing.

Siegfried Holding AG (XSWX:SFZN) Headlines

No Headlines